PVG Asset Management Corp Has $843,000 Stake in Anavex Life Sciences Corp. (NASDAQ:AVXL)

PVG Asset Management Corp grew its position in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) by 503.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 78,490 shares of the biotechnology company's stock after purchasing an additional 65,485 shares during the period. Anavex Life Sciences makes up approximately 4.0% of PVG Asset Management Corp's investment portfolio, making the stock its 5th biggest position. PVG Asset Management Corp owned 0.09% of Anavex Life Sciences worth $843,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. Vermillion Wealth Management Inc. bought a new position in shares of Anavex Life Sciences in the 4th quarter valued at about $34,000. Tower Research Capital LLC TRC lifted its holdings in shares of Anavex Life Sciences by 102.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,383 shares of the biotechnology company's stock valued at $36,000 after acquiring an additional 1,708 shares during the last quarter. Berkshire Money Management Inc. bought a new position in shares of Anavex Life Sciences in the 4th quarter valued at about $107,000. Prudential Financial Inc. bought a new position in shares of Anavex Life Sciences in the 4th quarter valued at about $109,000. Finally, D.A. Davidson & CO. bought a new position in shares of Anavex Life Sciences in the 4th quarter valued at about $122,000. Hedge funds and other institutional investors own 31.55% of the company's stock.

Anavex Life Sciences Stock Performance

NASDAQ AVXL traded up $0.21 during trading on Wednesday, hitting $7.58. The stock had a trading volume of 1,105,451 shares, compared to its average volume of 1,225,815. The stock has a market capitalization of $647.12 million, a price-to-earnings ratio of -13.78 and a beta of 0.82. Anavex Life Sciences Corp. has a one year low of $3.51 and a one year high of $14.44. The stock has a 50 day simple moving average of $8.65 and a 200 day simple moving average of $9.12.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.03. During the same quarter in the prior year, the company posted ($0.13) earnings per share. On average, sell-side analysts predict that Anavex Life Sciences Corp. will post -0.69 EPS for the current year.

Wall Street Analyst Weigh In

AVXL has been the subject of several analyst reports. HC Wainwright reissued a "buy" rating and issued a $42.00 price objective on shares of Anavex Life Sciences in a research note on Monday, April 7th. D. Boral Capital reissued a "buy" rating and issued a $46.00 price objective on shares of Anavex Life Sciences in a research note on Monday, April 7th.

Anavex Life Sciences Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.